Third US patent on Israeli Teva's MS drug Copaxone invalidated

September 1, 2016 22:14

NEW YORK- US patent officials on Thursday invalidated a third patent covering Israel's Teva Pharmaceutical Industries' $4 billion multiple sclerosis treatment Copaxone, after canceling two other patents on the drug last week.

The ruling came in a challenge at the US Patent and Trademark Office by Mylan NV, which is trying to bring out a generic version of the 40-milligram injectable drug, taken three times a week. According to the US Food and Drug Administration, Copaxone is protected by five patents in total.

Related Content

Breaking news
September 18, 2019
New York state ban on flavored e-cigarettes given final approval